Business Context and Reporting Period
Hercules Technology Growth Capital, Inc. (HTGC) is a specialty finance company and Business Development Company (BDC) focused on providing senior secured loans to venture capital-backed companies in technology, biotechnology, life science, and energy sectors. This Form 10-Q covers the quarterly period ended June 30, 2014.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|
| Total Investment Income | $69.8 million | $65.5 million |
| Net Investment Income | $36.9 million | $32.6 million |
| Net Realized Gain on Investments | $7.3 million | $4.2 million |
| Net Unrealized Depreciation | ($8.8 million) | $0.7 million (Appreciation) |
| Net Increase in Net Assets from Operations | $35.4 million | $37.6 million |
| Net Asset Value (NAV) per Share | $10.42 | $10.09 |
| Total Assets | $1.15 billion | $1.22 billion (Dec 31, 2013) |
| Total Liabilities | $490.6 million | $571.7 million (Dec 31, 2013) |
| Cash and Cash Equivalents | $116.0 million | $268.4 million (Dec 31, 2013) |
| Dividends Declared per Share | $0.62 | $0.55 |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased to $991.3 million from $910.3 million at year-end 2013. Debt investments grew to $898.0 million, while equity and warrant values adjusted due to warrant exercises and impairments.
- Unrealized Depreciation: The company recorded $8.8 million in net unrealized depreciation for the six months ended June 30, 2014, compared to $0.7 million in appreciation in the prior year period. This was driven by collateral-based impairments on debt and warrant investments, partially offset by equity appreciation.
- Debt Reduction: Total liabilities decreased significantly from $571.7 million to $490.6 million, primarily due to the repayment of $34.8 million in SBA debentures and the amortization of Asset-Backed Notes (reduced from $89.6 million to $46.5 million).
- Cash Position: Cash and cash equivalents declined from $268.4 million to $116.0 million, reflecting active deployment of capital into new investments ($283.2 million funded in debt securities) and dividend payments.
Guidance, Outlook, and Risks
- Outlook: Management continues to focus on originating new investments and reducing the cost of financing. The company expanded its investment team and broadened access to debt capital markets.
- Subsequent Events: On July 14, 2014, the company issued $100.0 million of 6.25% Senior Notes due 2024. Additionally, approximately $33.9 million of Convertible Senior Notes were converted into cash and stock in July and August 2014.
- Risks:
- Valuation Risk: Approximately 86.2% of assets are Level 3 investments valued in good faith by the Board, subject to significant judgment and potential volatility.
- Liquidity: The company relies on cash flows from operations and borrowings (SBA debentures, credit facilities) to fund commitments. Unfunded contractual commitments totaled $229.3 million.
- Portfolio Concentration: The top four industries (Drug Discovery, Energy Technology, Internet Services, Medical Devices) comprised 63.8% of the portfolio.
Investor Verification Checklist
- Verify the impact of the $8.8 million unrealized depreciation on future NAV and dividend sustainability.
- Confirm the status of the $229.3 million in unfunded contractual commitments and the company's ability to fund them given the reduced cash balance.
- Review the details of the subsequent $100 million 2024 Note issuance and its effect on leverage ratios.
- Monitor the conversion activity of the $75 million Convertible Senior Notes due 2016, which became convertible in July 2014.
- Assess the concentration risk in the Energy Technology and Drug Discovery sectors, which represent 38.1% of the portfolio.